Literature DB >> 17505573

[Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients].

Cristian Vallejos1, Leonardo Garrido, Dante Cáceres, Ana María Madrid, Claudia Defilippi, Carlos Defilippi, Héctor Toledo.   

Abstract

BACKGROUND: Helicobacter pylori is a pathogenic bacterium that infects a significant number of individuals. At present, therapeutic strategies to eradicate this bacterium depend on our knowledge of its resistance to antimicrobials. AIMS: To evaluate the primary resistance of H pylori to metronidazole (Mtz), clarithromycin (Cla), and tetracycline (Tet) in symptomatic out-patients.
MATERIAL AND METHODS: Fifty independent isolates of H pylori were obtained by endoscopy-assisted gastric biopsy from patients attending the University of Chile Clinical Hospital, that previously had not been treated with an eradication regime against this bacterium. The minimal inhibitory concentration of each antimicrobial was determined by agar dilution method.
RESULTS: Forty five and 27% of the isolates were found to be resistant to Mtz and Tet, respectively; the majority of these resistant isolates were from patients older than 21 years. Twenty percent of isolates were resistant to Cla; these were distributed evenly among different ages. Thirty two percent of the isolates were resistant to two or more of the antimicrobials.
CONCLUSIONS: The high frequency of naturally occurring, antimicrobial-resistant strains of H pylori poses a national and world-wide problem for public health.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505573     DOI: 10.4067/s0034-98872007000300002

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  13 in total

1.  Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.

Authors:  Alba A Trespalacios; William Otero; Jorge E Caminos; Marcela M Mercado; Jenny Avila; Liliana E Rosero; Azucena Arévalo; Raúl A Poutou-Piñales; David Y Graham
Journal:  J Microbiol       Date:  2013-08-30       Impact factor: 3.422

2.  14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.

Authors:  E Robert Greenberg; Garnet L Anderson; Douglas R Morgan; Javier Torres; William D Chey; Luis Eduardo Bravo; Ricardo L Dominguez; Catterina Ferreccio; Rolando Herrero; Eduardo C Lazcano-Ponce; María Mercedes Meza-Montenegro; Rodolfo Peña; Edgar M Peña; Eduardo Salazar-Martínez; Pelayo Correa; María Elena Martínez; Manuel Valdivieso; Gary E Goodman; John J Crowley; Laurence H Baker
Journal:  Lancet       Date:  2011-07-21       Impact factor: 79.321

3.  High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain.

Authors:  Sonia Agudo; Guillermo Pérez-Pérez; Teresa Alarcón; Manuel López-Brea
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

4.  In vitro effect of amoxicillin and clarithromycin on the 3' region of cagA gene in Helicobacter pylori isolates.

Authors:  Javier Andrés Bustamante-Rengifo; Andrés Januer Matta; Alvaro Pazos; Luis Eduardo Bravo
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

5.  Absence of Helicobacter pylori high tetracycline resistant 16S rDNA AGA926-928TTC genotype in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil.

Authors:  Rodrigo Buzinaro Suzuki; Cristiane Maria Almeida; Márcia Aparecida Sperança
Journal:  BMC Gastroenterol       Date:  2012-05-17       Impact factor: 3.067

6.  Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa.

Authors:  Patricio Gonzalez-Hormazabal; Maher Musleh; Susana Escandar; Hector Valladares; Enrique Lanzarini; V Gonzalo Castro; Lilian Jara; Zoltan Berger
Journal:  BMC Gastroenterol       Date:  2018-06-20       Impact factor: 3.067

7.  Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin.

Authors:  Türkan Sakinc; Barbara Baars; Nicole Wüppenhorst; Manfred Kist; Johannes Huebner; Wolfgang Opferkuch
Journal:  BMC Res Notes       Date:  2012-10-30

8.  Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile.

Authors:  Laura Otth; Myra Wilson; Heriberto Fernández; Carola Otth; Claudio Toledo; Victoria Cárcamo; Paula Rivera; Luis Ruiz
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

9.  Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients.

Authors:  Simone Ulrich Picoli; Luiz Edmundo Mazzoleni; Heriberto Fernández; Laura Renata De Bona; Erli Neuhauss; Larisse Longo; João Carlos Prolla
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 May-Jun       Impact factor: 1.846

10.  Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients.

Authors:  Meryem Bachir; Rachida Allem; Abedelkarim Tifrit; Meriem Medjekane; Amine El-Mokhtar Drici; Mustafa Diaf; Kara Turki Douidi
Journal:  Braz J Microbiol       Date:  2018-02-13       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.